Supernus Pharmaceuticals | SUPN - Ebit



金融业
股票价格
USD
资产
USD 1.43B
现金及等价物
USD 179.95M
销售成本
USD 59M
流动资产
USD 723.5M
流动负债
USD 347.38M
债务
USD 40.17M
EBIT
USD -21.04M
EBITDA
USD 31.6M
员工
674
EPS每股收益
USD -1.01
股本和储备
USD 1.03B
销售毛利
USD 160.06M
债务利息支出
USD 910K
利息收入
USD 2.63M
贷款资金
USD 400.38M
市值
USD 2.56B
净收入
USD -58.37M
营业费用
USD 1.03B
营业利润
USD -21.04M
普通股股本
USD 58.16M
PE价格收益
65.37
税前利润
USD -57.65M
销售收入
USD 219.1M
销售和管理费用
USD 133.64M
股票
USD 107.03M
贸易债权人
USD 5.59M
应收帐款人
USD 211.66M


Ebit 更改 日
Abbott USD 2.13B 281M 2026-06
ANI Pharmaceuticals USD 39.84M 1.13M 2026-06
Aurora Cannabis CAD 7.12M 42.91M 2026-03
Bristol-Myers Squibb USD 299M 3.26B 2026-06
Canopy Growth CAD -145.65M 132.99M 2026-03
Cara Therapeutics USD -7.05M 1.11M 2026-03
Corcept Therapeutics USD 41.3M 90.9M 2026-06
Eisai JPY 24.73B 35.04B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Novo Nordisk DKK 33.76B 25.86B 2026-06
Pacira USD 9.96M 5.33M 2026-06
Perrigo USD 33.6M 50.8M 2026-03
Pfizer USD -180M 5.16B 2026-06
Supernus Pharmaceuticals USD -21.04M 14.21M 2026-06
United Therapeutics USD 375.6M 49.8M 2026-06
Xeris Pharmaceuticals USD 9.12M 7.65M 2026-03